Archive for 2011
January 26th, 2011. Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma
Conclusions: The determination of histological subtype from a diagnostic biopsy is difficult due to sampling error, but an adequate specimen obtained from surgical biopsy increases the accuracy of subtype classification compared with radiological-guided biopsies.
Posted in Biphasic or Mixed, CT or CAT scan, Diagnosis & Differentiation, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Surgery, thoracoscopy, thoracotomy, Type of Assessment:, Type of Mesothelioma: | 4 Comments »
January 26th, 2011. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies
However, none of these has yet reached daily practice. That is the reason why efforts must continue in the area of clinical and translational research for MPM.
January 25th, 2011. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
Conclusions: In our series of carboplatin-/pemetrexed-treated MPM patients, low TS protein and mRNA levels were significantly associated to DC, improved PFS, and OS. Prospective trials for the validation of the prognostic/predictive role of TS in MPM patients treated with pemetrexed-based regimens are warranted.
January 25th, 2011. Thoracoscopic extrapleural pneumonectomy for mesothelioma
Surgical therapy offers limited cure benefits at the cost of high morbidity. Although technically challenging and performed rarely, a less invasive approach to extrapleural pneumonectomy was developed with the intent to speed convalescence, hasten adjuvant therapies, improve quality of life, and reduce wound surface area for possible tumor contamination.
January 25th, 2011. Antioxidants Prevent the RhoA Inhibition Evoked by Crocidolite Asbestos in Human Mesothelial and Mesothelioma Cells
Conclusions: Such a mechanism could at least partly explain the effects exerted by crocidolite fibers in mesothelial cells.
January 25th, 2011. miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer
Conclusions: Serum miRNAs are differentially expressed between patients with early-stage NSCLC and controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation.
January 25th, 2011. Occupational Respiratory Cancer in Korea
Occupational respiratory cancer has increased during the last 10 to 20 yr though carcinogen-exposed population has declined in the same period. More efforts to advance the systems for the investigation, prevention and management of occupational respiratory cancer are needed.
January 20th, 2011. LATS2 Is a Tumor Suppressor Gene of Malignant Mesothelioma
Because NF2 is genetically mutated in 40% to 50% of MM, our data indicate that Hippo pathway dysregulation is frequent in MM cells with inactivation of LATS2 or an upstream regulator of this pathway, Merlin, which is encoded by NF2. Thus, our results suggest that the inactivation of LATS2 is one of the key mechanisms for constitutive activation of YAP, which induces deregulation of MM cell proliferation.
January 20th, 2011. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma
HSP90 inhibition also suppressed phosphorylation of downstream signaling intermediates (AKT, mitogen-activated protein kinase, and S6); upregulated the p53, p21, and p27 cell cycle checkpoints; induced G(2) phase arrest; induced caspase 3/7 activity; and led to an increase in the sub-G(1) apoptotic population. These compelling proapoptotic and antiproliferative responses indicate that HSP90 inhibition warrants clinical evaluation as a novel therapeutic strategy in mesothelioma.
January 19th, 2011. Biological Materials for Diaphragmatic Repair: Initial Experiences with the PeriGuard Repair Patch®
Conclusion: We consider the PeriGuard Repair Patch® a viable alternative to synthetic materials for diaphragm replacement. Moreover, we advise carrying out cautious follow-up in patients undergoing extensive oncological resection to learn more about the biological behavior of the bovine PeriGuard Repair Patch® after diaphragmatic repair.
January 18th, 2011. Exposure to asbestos: correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes
Concerning micro-nucleated lymphocytes, a statistically significant difference from controls was seen in the percentages of both micro-nucleated mononucleated lymphocytes (MnMNL) and micro-nucleated binucleated lymphocytes (MnBNL), but the difference was markedly higher for the percentage of micro-nucleated polynucleated lymphocytes (MnPNL). With respect to the correlation between the frequency of the three types of micronucleated lymphocytes and serum-SMRP values of asbestos-exposed subjects, it was statistically significant for MnMNL, but not for MnBNL and MnPNL.
January 18th, 2011. Clinical-therapeutic management of thoracoscopy in pleural effusion: a groundbreaking technique in the twenty-first century
Conclusions: Our results indicate that thoracoscopy is a cost-effective and reliable technique for obtaining histological diagnosis in PE and also allows a directed pleurodesis if indicated.
January 15th, 2011. Validation of tissue microarray technology in malignant pleural mesothelioma
Conclusion: If a minimum of four cores is used, TMA is an appropriate method for immunohistochemistry in MPM.
January 14th, 2011. Dasatinib: An Anti-Tumour Agent via Src Inhibition
The most common non-haematologic adverse events include gastrointestinal symptoms (diarrhoea, nausea, vomiting, abdominal pain and anorexia), headache, peripheral edema, and pleural effusion. In respect of these encouraging studies investigating dasatinib in the treatment of patients with GIST, prostate cancer, multiple myeloma and sarcomas, ongoing phase III clinical trials warrant the drug evaluation as recommended agent for the treatment of these diseases, also in association with chemoterapy or other targeted therapies.
January 14th, 2011. mesothelioma cell proliferation requires p38δ mitogen activated protein kinase and C/EBP-α
Furthermore, TGF-β inhibited PDGF-BB induced proliferation by interruption of p38 MAPK signalling. From this rat model, we conclude that in pleural mesothelioma, p38δ in C/EBP-α mediate proliferation and thus may represent new targets in mesothelioma therapy.
January 13th, 2011. Indication of Peritonectomy for Peritoneal Dissemination
Peritonectomy combined with perioperative chemotherapy may achieve long - term survival in a selected group of patients with PC. The higher mortality rate underlines this necessarily strict selection that should be reserved to experienced institutions.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Peritonectomy, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 12th, 2011. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
In conclusion, re-treatment with PBC should be considered as second-line therapy in MPM patients achieving a durable (>12 months) disease control with first-line PBC. Further prospective evaluation of this therapeutic option is warranted.
January 12th, 2011. Phase I Studies of CBP501,a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
Conclusions: CBP501 is well tolerated in patients as monotherapy and with cisplatin. At the recommended phase 2 dose (RP2D) the combination is feasible and HRS manageable with prophylaxis. Evidence of anti-tumor activity was observed in platinum-resistant patients.
January 8th, 2011. The pleura in health and disease
, laterality) is often of great value to the pathologist in arriving at a correct diagnosis. Similarly, knowledge of the normal anatomical considerations and familiarity with the expected pleural histopathology for the most clinically relevant pleural diseases are critical assets for pulmonary physicians in providing optimal care for their patients.
January 7th, 2011. Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion
These are usually found in mediastinal and abdominal lymph nodes and are associated with effusions. We report a case of benign mesothelial cell inclusions in cervical lymph nodes, which was associated with chylous effusion, and immunohistochemistry revealed unusual weak cytoplasmic epithelial membrane antigen positivity in the cells.
|
|  |
